Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.33 |
| ▸ | TUBB | P07437 | 2/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188172 | 0.88 | TUBB4A (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL588757 | 0.83 | KDR (0.39) | CYP3A4CYP3A5AAK1MAP2K4AURKA | |
| SCHEMBL589284 | 0.80 | EGFR (0.47) | EGFRITK | |
| SCHEMBL8212259 | 0.74 | MAP2K4 (0.40) | MAP2K4SLC22A12SCN9A | |
| SCHEMBL21341394 | 0.74 | ROCK2 (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13846975 | 0.72 | EGFR (0.43) | EGFRITKAURKACDK2SLC22A12 | |
| SCHEMBL7605898 | 0.71 | ELANE (0.44) | CYP3A4MAP2K4SLC22A12 | |
| SCHEMBL14771756 | 0.71 | SYK (0.33) | EGFRITK | |
| SCHEMBL12975335 | 0.71 | AAK1 (0.33) | AAK1MAP2K4 | |
| SCHEMBL19967692 | 0.71 | STK17B (0.36) | AAK1MAP2K4AURKACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277258-A1 | Chemical Compounds | LEO OSPREY LIMITED (JE) | 2012-11-01 | — | — | US | disclosed |
| US-8114885-B2 | Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer | GLAXOSMITHKLINE LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7858626-B2 | Pyrimidineamines as angiogenesis modulators | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| EP-1343782-B1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-12-20 | — | — | US | disclosed |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | NOVARTIS AG (CH) | 2007-11-22 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | TUBB4A 467/4885TUBB 551/4885TUBA3C 2124/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | TUBB4A 1076/4885TUBB 823/4885TUBA3C 1880/4885 |
| US-20100105712-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | TUBB4A 1076/4885TUBB 823/4885TUBA3C 1880/4885 |
| US-20120277258-A1 | Chemical Compounds | KDR, FLT4, FLT1 | TUBB4A 1076/4885TUBB 823/4885TUBA3C 1880/4885 |
| US-20070270427-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | TUBB4A 1076/4885TUBB 823/4885TUBA3C 1880/4885 |
| US-20070292513-A1 | CHEMICAL COMPOUNDS | KDR, FLT4, FLT1 | TUBB4A 1076/4885TUBB 823/4885TUBA3C 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.